¼¼°èÀÇ ¼ÒȰü Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø : ÀǾàǰ À¯Çüº°, ¿ëµµº°, À¯Åë ä³Îº° ¹× Áö¿ªº° ºÐ¼®(2023-2030³â)
Global Gastrointestinal Therapeutics Market Size Study & Forecast, by Drug Class, by Application, by Distribution Channel and Regional Analysis, 2023-2030
»óǰÄÚµå
:
1401386
¸®¼Ä¡»ç
:
Bizwit Research & Consulting LLP
¹ßÇàÀÏ
:
2023³â 11¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹®
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¼¼°è ¼ÒȰü Ä¡·áÁ¦ ½ÃÀåÀº 2022³â ¾à 395¾ï ´Þ·¯·Î Æò°¡µÇ¾ú°í, ¿¹Ãø ±â°£ÀÎ 2023-2030³â 5% ÀÌ»óÀÇ °ß½ÇÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼ÒȰü Ä¡·áÁ¦´Â ¼ÒȰü¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Àå¾Ö¸¦ ½Äº°ÇÏ°í °ü¸®ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÏ´Â ÀÇÇÐÀÇ Æ¯Á¤ ºÐ¾ßÀÔ´Ï´Ù. ÁÖ·Î À§, ¼ÒÀå, ´ëÀå, Á÷Àå°ú °°Àº ¼Òȱâ°ü¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¹®Á¦¸¦ Ä¡·áÇÏ´Â µ¥ ÁÖ·ÂÇÕ´Ï´Ù. Áõ»óÀ» ¿ÏÈÇϰí, À§Àå ½Ã½ºÅÛÀÇ Àü¹ÝÀûÀÎ ±â´ÉÀ» °³¼±Çϸç, ÀÌ·¯ÇÑ Áõ»óÀ¸·Î °íÅë¹Þ´Â »ç¶÷µéÀÇ »îÀÇ ÁúÀ» Çâ»ó½Ã۱â À§ÇØ ¾à¹°À» Æ÷ÇÔÇÑ ´Ù¾çÇÑ °³ÀÔÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ Ä¡·áÁ¦ ½ÃÀåÀº À§Àå Àå¾Ö ¹ß»ý·ü Áõ°¡, ³ëÀÎ Àα¸ Áõ°¡, ÁÖ¿ä ±â¾÷µéÀÇ ½ÅÁ¦Ç° Ãâ½Ã µîÀÇ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÂÀο¡ ´ëÇÑ Á¤ºÎÀÇ ¾ö°ÝÇÑ ±ÔÁ¦¿Í 2023-2030³âÀÇ ¿¹Ãø ±â°£ µ¿¾È ÀǾàǰÀÇ Æ¯Çã°¡ ¸¸·áµÇ´Â °ÍÀº ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
À§½Äµµ¿ª·ùÁúȯ(GERD), °ú¹Î¼º´ëÀåÁõÈıº(IBS), À§Àå¾Ï°ú °°Àº À§Àå ÁúȯÀÇ À¯º´·üÀÌ ±ÞÁõÇÏ¸é¼ ¼ÒȰü Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀÌ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ¹Ì±¹ Áٱ⼼Æ÷ Àç´ÜÀÇ ¹ßÇ¥¿¡ µû¸£¸é, 2023³â¿¡´Â 80¿© Á¾ÀÇ ÀÚ°¡¸é¿ªÁúȯÀÌ ¼¼°è Àα¸ÀÇ ¾à 4%¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, °¡Àå ¸¹Àº ÁúȯÀº 1Çü ´ç´¢º´, ·ù¸¶Æ¼½º °üÀý¿°, ·çǪ½º, Å©·Ðº´, ´Ù¹ß¼º °æÈÁõ, ÇǺΰæÈÁõ, °Ç¼± µîÀÔ´Ï´Ù. ¶ÇÇÑ, ¼Òȱâ Áúȯ¿¡ Ãë¾àÇÑ ³ë³âÃþÀÌ Áõ°¡ÇÏ¸é¼ ¼ÒȰü Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ ±¹¸³»ý¹°°øÇÐÁ¤º¸¼¾ÅÍ(NCBI)°¡ 2023³â¿¡ ¹ßÇ¥ÇÑ ³í¹®¿¡ µû¸£¸é, ¿°Áõ¼º ÀåÁúȯ(IBD)ÀÇ ºÎ´ãÀº ¼¼°èÀûÀ¸·Î Áõ°¡Çϰí ÀÖÀ¸¸ç, ƯÈ÷ ³ë³âÃþ¿¡¼ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀ¸·Î º¸°íµÆ½À´Ï´Ù. ¶ÇÇÑ, ¼Òȱâ Áúȯ°ú Ä¡·á¹ý¿¡ ´ëÇÑ È¯ÀÚµéÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼ Áø´ÜÀ² Áõ°¡¿Í Ä¡·áÁ¦ ¼ö¿ä Áõ°¡·Î À̾îÁ® ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀǾàǰ ¿¬±¸ °³¹ßÀÇ ¹ßÀüÀº ½Å¾à, »õ·Î¿î Àü´Þ ½Ã½ºÅÛ ¹× Ç¥Àû Ä¡·á¹ýÀÇ ¹ß°ßÀ¸·Î À̾îÁ® ½ÃÀå¿¡ ±âȸ¸¦ °¡Á®´ÙÁÖ°í ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·á, »ý¹°ÇÐÀû Á¦Á¦, °³ÀÎ ¸ÂÃãÇü Ä¡·á Á¢±Ù¹ýÀº ´Ù¾çÇÑ ¼Òȱâ Áúȯ¿¡ ´ëÇÑ Ä¡·á ¿É¼ÇÀ» È®ÀåÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 6¿ù, ¾Öºêºñ´Â ¸®»êŰÁÖ¸¿(SKYRIZI)ÀÌ Áߵ¿¡¼ ÁßÁõÀÇ È°µ¿¼º ±Ë¾ç¼º ´ëÀå¿° ¼ºÀΠȯÀÚ¿¡¼ 1Â÷ Æò°¡º¯¼öÀÎ 52ÁÖ° ÀÓ»óÀû °üÇØ¸¦ ´Þ¼ºÇϰí, 2Â÷ Æò°¡º¯¼öµµ ´Þ¼ºÇÑ 3»ó À¯Áö¿ä¹ý ½ÃÇè COMMANDÀÇ ¾çÈ£ÇÑ Å¾¶óÀÎ °á°ú¸¦ ¹ßÇ¥Çß½À´Ï´Ù.
¼¼°èÀÇ ¼ÒȰü Ä¡·áÁ¦ ½ÃÀå Á¶»ç¿¡¼ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«À̸ç, 2022³â¿¡´Â ºÏ¹Ì°¡ ¼ÒȰü Ä¡·áÁ¦ÀÇ ÁÖ¿ä ½ÃÀåÀ¸·Î ºÎ»óÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àß ±¸ÃàµÈ ÀÇ·á ÀÎÇÁ¶ó, ³ôÀº ±¸¸Å·Â, ¼ÒȰü Ä¡·áÁ¦ÀÇ Ã¤Åà Áõ°¡µµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çß½À´Ï´Ù. ¶ÇÇÑ, ÀÌ Áö¿ªÀÇ ÁÖ¿ä ±â¾÷µéÀÌ ½ÅÁ¦Ç°À» Ãâ½ÃÇϰí Á¦Ç° ½ÂÀÎÀ» ȹµæÇÑ °Íµµ ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ½Ä½À°ü º¯È, µµ½ÃÈ, ¶óÀÌÇÁ½ºÅ¸ÀÏ º¯È, °í·ÉÈ·Î ÀÎÇÑ ¼Òȱâ Áúȯ À¯º´·ü Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È Å« ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÌ ¿¬±¸ÀÇ ¸ñÀûÀº ÃÖ±Ù ¸î ³â°£ ´Ù¾çÇÑ ºÎ¹®°ú ±¹°¡ ½ÃÀå ±Ô¸ð¸¦ ÆÄ¾ÇÇϰí ÇâÈÄ ¸î ³â°£ ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ º¸°í¼´Â Á¶»ç ´ë»ó ±¹°¡ÀÇ »ê¾÷ÀÇ ÁúÀû/¾çÀû Ãø¸éÀ» ¸ðµÎ Æ÷ÇÔÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.
¶ÇÇÑ ½ÃÀåÀÇ ¹Ì·¡ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀΰú °úÁ¦¿Í °°Àº Áß¿äÇÑ Ãø¸é¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸µµ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä ±â¾÷ÀÇ °æÀï ±¸µµ¿Í Á¦Ç° Á¦°ø¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚµéÀÌ ÅõÀÚÇÒ ¼ö ÀÖ´Â ¹Ì½ÃÀû ½ÃÀå¿¡¼ÀÇ ÀáÀçÀû ±âȸµµ Æ÷ÇÔÇÕ´Ï´Ù.
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ¼¼°èÀÇ ¼ÒȰü Ä¡·áÁ¦ ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
- Á¶»ç ¸ñÀû
- ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
- Á¶»ç ´ë»ó³âµµ
- ÅëÈ È¯»êÀ²
Á¦3Àå ¼¼°èÀÇ ¼ÒȰü Ä¡·áÁ¦ ½ÃÀå ¿ªÇÐ
- ¼ÒȰü Ä¡·áÁ¦ ½ÃÀå ¿µÇ⠺м®(2020³â-2030³â)
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
- ½ÃÀå ±âȸ
Á¦4Àå ¼¼°èÀÇ ¼ÒȰü Ä¡·áÁ¦ ½ÃÀå »ê¾÷ ºÐ¼®
- Porter's Five Forces ¸ðµ¨
- °ø±Þ ±â¾÷ÀÇ ±³¼··Â
- ¹ÙÀ̾îÀÇ ±³¼··Â
- ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
- ´ëüǰÀÇ À§Çù
- °æÀï ±â¾÷°£ °æÀï °ü°è
- Porter's Five ForcesÀÇ ¿µÇ⠺м®
- PEST ºÐ¼®
- Á¤Ä¡
- °æÁ¦
- »çȸ
- 񃬣
- ȯ°æ
- ¹ý·ü
- ÁÖ¿ä ÅõÀÚ ±âȸ
- ÁÖ¿ä ¼º°ø Àü·«
- COVID-19ÀÇ ¿µÇ⠺м®
- ÆÄ±«Àû µ¿Çâ
- ¾÷°è Àü¹®°¡ÀÇ °ßÇØ
- ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð ¹× Á¦¾È
Á¦5Àå ¼¼°èÀÇ ¼ÒȰü Ä¡·áÁ¦ ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°
- ½ÃÀå ÇöȲ
- ¼¼°èÀÇ ¼ÒȰü Ä¡·áÁ¦ ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°, ½ÇÀû-°¡´É¼º ºÐ¼®
- ¼¼°èÀÇ ¼ÒȰü Ä¡·áÁ¦ ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº° ÃßÁ¤¡¤¿¹Ãø, 2020³â-2030³â
- ¼ÒȰü Ä¡·áÁ¦ ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
- »ý¹°Á¦Á¦
- Ç÷ÎÅæ ÆßÇÁ ¾ïÁ¦Á¦
- ¾Æ¹Ì³ë »ì¸®½Ç»ê¿°
- Á¦»êÁ¦
- ¿ÏÇÏÁ¦
- H2 ±æÇ×Á¦
- ±âŸ
Á¦6Àå ¼¼°èÀÇ ¼ÒȰü Ä¡·áÁ¦ ½ÃÀå : ¿ëµµº°
- ½ÃÀå ÇöȲ
- ¼¼°èÀÇ ¼ÒȰü Ä¡·áÁ¦ ½ÃÀå : ¿ëµµº°, ½ÇÀû-°¡´É¼º ºÐ¼®
- ¼¼°èÀÇ ¼ÒȰü Ä¡·áÁ¦ ½ÃÀå : ¿ëµµº° ÃßÁ¤¡¤¿¹Ãø, 2020³â-2030³â
- ¼ÒȰü Ä¡·áÁ¦ ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
- ¿°Áõ¼º ÀåÁúȯ
- À§½Äµµ ¿ª·ùÁõ
- ¼Òȼº ±Ë¾ç Áúȯ
- °ú¹Î¼º ÀåÁõÈıº
- ±âŸ
Á¦7Àå ¼¼°èÀÇ ¼ÒȰü Ä¡·áÁ¦ ½ÃÀå : À¯Åë ä³Îº°
- ½ÃÀå ÇöȲ
- ¼¼°èÀÇ ¼ÒȰü Ä¡·áÁ¦ ½ÃÀå : À¯Åë ä³Îº°, ½ÇÀû-°¡´É¼º ºÐ¼®
- ¼¼°èÀÇ ¼ÒȰü Ä¡·áÁ¦ ½ÃÀå : À¯Åë ä³Îº° ÃßÁ¤¡¤¿¹Ãø, 2020³â-2030³â
- ¼ÒȰü Ä¡·áÁ¦ ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
- º´¿ø ¾à±¹
- µå·°½ºÅä¾î
- ¼Ò¸Å ¾à±¹
- ¿Â¶óÀÎ °ø±Þ¾÷ü
Á¦8Àå ¼¼°èÀÇ ¼ÒȰü Ä¡·áÁ¦ ½ÃÀå : Áö¿ªº° ºÐ¼®
- ÁÖ¿ä ±¹°¡
- ÁÖ¿ä ½ÅÈï ±¹°¡
- ¼ÒȰü Ä¡·áÁ¦ ½ÃÀå, Áö¿ªº° ½ÃÀå ÇöȲ
- ºÏ¹Ì
- À¯·´ÀÇ ¼ÒȰü Ä¡·áÁ¦ ½ÃÀå ÇöȲ
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ½ºÆäÀÎ
- ÀÌÅ»¸®¾Æ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¼ÒȰü Ä¡·áÁ¦ ½ÃÀå ÇöȲ
- Áß±¹
- Àεµ
- ÀϺ»
- È£ÁÖ
- Çѱ¹
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ¼ÒȰü Ä¡·áÁ¦ ½ÃÀå ÇöȲ
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦9Àå °æÀï Á¤º¸
- ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®
- ÁÖ¿ä ½ÃÀå Àü·«
- ±â¾÷ °³¿ä
- Bristol-Myers Squibb Company
- ÁÖ¿ä Á¤º¸
- °³¿ä
- À繫(µ¥ÀÌÅÍ ÀÔ¼ö°¡ °¡´ÉÇÑ °æ¿ì)
- Á¦Ç° °³¿ä
- ÃÖ±Ù µ¿Çâ
- AbbVie Inc.
- Pfizer Inc.
- AstraZeneca plc
- Bayer AG
- Takeda Pharmaceutical Company Limited
- Organon Group of Companies
- Bausch Health Companies Inc.
- Cosmo Pharmaceuticals N.V.
- Teva Pharmaceutical Industries Limited
Á¦10Àå Á¶»ç °úÁ¤
- Á¶»ç °úÁ¤
- µ¥ÀÌÅÍ ¸¶ÀÌ´×
- ºÐ¼®
- ½ÃÀå ÃßÁ¤
- °ËÁõ
- ÃâÆÇ
- Á¶»ç ¼Ó¼º
- Á¶»çÀÇ ÀüÁ¦Á¶°Ç
LSH
¿µ¹® ¸ñÂ÷
Global Gastrointestinal Therapeutics Market is valued at approximately USD 39.5 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 5% over the forecast period 2023-2030. Gastrointestinal therapeutics is a specific area of medicine that aims to identify and manage disorders that affect the gastrointestinal tract. It is primarily concerned with treating issues that affect the organs within the gastrointestinal system, such as the stomach, small intestine, large intestine, and rectum. It involves various interventions, including medications that aim to alleviate symptoms, improve the overall function of the gastrointestinal system, and enhance the quality of life for individuals affected by these conditions. The market for these treatments is driven by factors such as an increase in the incidence of gastrointestinal disorders, a growing geriatric population, and the launch of new products by key companies. However, the market growth is hindered by strict government regulations regarding the approval of biosimilars and the expiration of drug patents during the forecast period of 2023-2030.
The growth of the gastrointestinal therapeutics market is being fueled by a surge in the prevalence of gastrointestinal diseases such as Gastroesophageal Reflux Disease (GERD), Irritable Bowel Syndrome (IBS), and gastrointestinal cancers. According to an article published by the National Stem Cell Foundation, in 2023, over 80 different autoimmune diseases affect nearly 4% of the world population, with the most common being type 1 diabetes, rheumatoid arthritis, lupus, Crohn's disease, multiple sclerosis , scleroderma, and psoriasis. Additionally, the increase in elderly individuals who are more susceptible to gastrointestinal conditions has led to a rise in demand for gastrointestinal therapeutics. According to an article published by the National Center for Biotechnology and Information (NCBI) in 2023, which reported that the burden of inflammatory bowel disease (IBD) is increasing worldwide, with a particular increase in prevalence in the elderly population. Furthermore, patients increased awareness of gastrointestinal disorders and available treatments has led to higher diagnosis rates and increased demand for therapeutics, contributing to market growth. Advances in pharmaceutical research and development have also led to the discovery of new drugs, novel delivery systems, and targeted therapies, providing opportunities for the market. Precision medicine, biologics, and personalized treatment approaches are expanding the treatment options available for various gastrointestinal conditions. For example, in June 2023, AbbVie Inc. announced positive top-line results from its Phase 3 maintenance study, COMMAND, showing Risankizumab (SKYRIZI) achieved the primary endpoint of clinical remission at week 52, as well as key secondary endpoints in adult patients with moderately to severely active ulcerative colitis.
The key regions considered for the Global Gastrointestinal Therapeutics Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. In 2022, North America was the dominant market for gastrointestinal therapeutics due to the presence of several major players in the region. The well-established healthcare infrastructure, high purchasing power, and increased adoption of gastrointestinal therapeutics also contributed to the market's growth. Additionally, key players in the region launched new products and obtained product approvals, further boosting market growth. Asia Pacific is expected to experience significant growth over the forecast period due to factors such as changing dietary habits, urbanization, lifestyle shifts, and an aging population leading to a rise in the prevalence of gastrointestinal disorders.
Major market player included in this report are:
- Bristol-Myers Squibb Company
- AbbVie Inc.
- Pfizer Inc.
- AstraZeneca plc
- Bayer AG
- Takeda Pharmaceutical Company Limited
- Organon Group of Companies
- Bausch Health Companies Inc.
- Cosmo Pharmaceuticals N.V.
- Teva Pharmaceutical Industries Limited
Recent Developments in the Market:
- In May 2023, AbbVie announced that RINVOQ has been approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderately to severely active Crohn's disease who have not responded well to one or more TNF blockers, or cannot tolerate them. Additionally, in April 2023, AbbVie reported that RINVOQ has also been approved by the European Commission (EC) as the first oral Janus Kinase (JAK) inhibitor to treat adult patients with moderately to severely active Crohn's disease.
- In May 2021, Bristol Myers Squibb made an announcement that the U.S. Food and Drug Administration (FDA) approved Zeposia (ozanimod) 0.92 mg to treat adults with moderately to severely active ulcerative colitis (UC), which is a chronic Inflammatory Bowel Disease (IBD).
- In January 2021, AstraZeneca, and Daiichi Sankyo Company, Limited announced the U.S. approval for Enhertu to treat HER2-positive Gastric or Gastroesophageal Junction (GEJ) adenocarcinoma in adults who have received a previous trastuzumab-based regimen.
Global Gastrointestinal Therapeutics Market Report Scope:
- Historical Data - 2020 - 2021
- Base Year for Estimation - 2022
- Forecast period - 2023-2030
- Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
- Segments Covered - Drug Class, Application, Distribution Channel, Region
- Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
- Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Class:
- Biologics
- Proton Pump Inhibitors
- Aminosalicylates
- Antacids
- Laxatives
- H2 Antagonists
- Others
By Application:
- Inflammatory Bowel Disease
- Gastroesophageal Reflux Disease
- Peptic Ulcer Disease
- Irritable Bowel Syndrome
- Others
By Distribution Channel:
- Hospitals Pharmacies
- Drug Stores
- Retail Pharmacies
- Online Providers
By Region:
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
- Latin America
- Brazil
- Mexico
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Table of Contents
Chapter 1. Executive Summary
- 1.1. Market Snapshot
- 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
- 1.2.1. Gastrointestinal Therapeutics Market, by Region, 2020-2030 (USD Billion)
- 1.2.2. Gastrointestinal Therapeutics Market, by Drug Class, 2020-2030 (USD Billion)
- 1.2.3. Gastrointestinal Therapeutics Market, by Application, 2020-2030 (USD Billion)
- 1.2.4. Gastrointestinal Therapeutics Market, by Distribution Channel, 2020-2030 (USD Billion)
- 1.3. Key Trends
- 1.4. Estimation Methodology
- 1.5. Research Assumption
Chapter 2. Global Gastrointestinal Therapeutics Market Definition and Scope
- 2.1. Objective of the Study
- 2.2. Market Definition & Scope
- 2.2.1. Industry Evolution
- 2.2.2. Scope of the Study
- 2.3. Years Considered for the Study
- 2.4. Currency Conversion Rates
Chapter 3. Global Gastrointestinal Therapeutics Market Dynamics
- 3.1. Gastrointestinal Therapeutics Market Impact Analysis (2020-2030)
- 3.1.1. Market Drivers
- 3.1.1.1. Increase in prevalence of gastrointestinal diseases
- 3.1.1.2. Rise in geriatric population
- 3.1.1.3. Rise in the number of product launches
- 3.1.2. Market Challenges
- 3.1.2.1. Stringent government regulations toward approval of biosimilars
- 3.1.2.2. Expiration of the drugs patent
- 3.1.3. Market Opportunities
- 3.1.3.1. Rise in Research & Development activities
- 3.1.3.2. Growth opportunities in emerging markets
Chapter 4. Global Gastrointestinal Therapeutics Market Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.2. Porter's 5 Force Impact Analysis
- 4.3. PEST Analysis
- 4.3.1. Political
- 4.3.2. Economical
- 4.3.3. Social
- 4.3.4. Technological
- 4.3.5. Environmental
- 4.3.6. Legal
- 4.4. Top investment opportunity
- 4.5. Top winning strategies
- 4.6. COVID-19 Impact Analysis
- 4.7. Disruptive Trends
- 4.8. Industry Expert Perspective
- 4.9. Analyst Recommendation & Conclusion
Chapter 5. Global Gastrointestinal Therapeutics Market, by Drug Class
- 5.1. Market Snapshot
- 5.2. Global Gastrointestinal Therapeutics Market by Drug Class, Performance - Potential Analysis
- 5.3. Global Gastrointestinal Therapeutics Market Estimates & Forecasts by Drug Class 2020-2030 (USD Billion)
- 5.4. Gastrointestinal Therapeutics Market, Sub Segment Analysis
- 5.4.1. Biologics
- 5.4.2. Proton Pump Inhibitors
- 5.4.3. Aminosalicylates
- 5.4.4. Antacids
- 5.4.5. Laxatives
- 5.4.6. H2 Antagonists
- 5.4.7. Others
Chapter 6. Global Gastrointestinal Therapeutics Market, by Application
- 6.1. Market Snapshot
- 6.2. Global Gastrointestinal Therapeutics Market by Application, Performance - Potential Analysis
- 6.3. Global Gastrointestinal Therapeutics Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
- 6.4. Gastrointestinal Therapeutics Market, Sub Segment Analysis
- 6.4.1. Inflammatory Bowel Disease
- 6.4.2. Gastroesophageal Reflux Disease
- 6.4.3. Peptic Ulcer Disease
- 6.4.4. Irritable Bowel Syndrome
- 6.4.5. Others
Chapter 7. Global Gastrointestinal Therapeutics Market, by Distribution Channel
- 7.1. Market Snapshot
- 7.2. Global Gastrointestinal Therapeutics Market by Distribution Channel, Performance - Potential Analysis
- 7.3. Global Gastrointestinal Therapeutics Market Estimates & Forecasts by Distribution Channel 2020-2030 (USD Billion)
- 7.4. Gastrointestinal Therapeutics Market, Sub Segment Analysis
- 7.4.1. Hospitals Pharmacies
- 7.4.2. Drug Stores
- 7.4.3. Retail Pharmacies
- 7.4.4. Online Providers
Chapter 8. Global Gastrointestinal Therapeutics Market, Regional Analysis
- 8.1. Top Leading Countries
- 8.2. Top Emerging Countries
- 8.3. Gastrointestinal Therapeutics Market, Regional Market Snapshot
- 8.4. North America Gastrointestinal Therapeutics Market
- 8.4.1. U.S. Gastrointestinal Therapeutics Market
- 8.4.1.1. Drug Class breakdown estimates & forecasts, 2020-2030
- 8.4.1.2. Application breakdown estimates & forecasts, 2020-2030
- 8.4.1.3. Distribution Channel breakdown estimates & forecasts, 2020-2030
- 8.4.2. Canada Gastrointestinal Therapeutics Market
- 8.5. Europe Gastrointestinal Therapeutics Market Snapshot
- 8.5.1. U.K. Gastrointestinal Therapeutics Market
- 8.5.2. Germany Gastrointestinal Therapeutics Market
- 8.5.3. France Gastrointestinal Therapeutics Market
- 8.5.4. Spain Gastrointestinal Therapeutics Market
- 8.5.5. Italy Gastrointestinal Therapeutics Market
- 8.5.6. Rest of Europe Gastrointestinal Therapeutics Market
- 8.6. Asia-Pacific Gastrointestinal Therapeutics Market Snapshot
- 8.6.1. China Gastrointestinal Therapeutics Market
- 8.6.2. India Gastrointestinal Therapeutics Market
- 8.6.3. Japan Gastrointestinal Therapeutics Market
- 8.6.4. Australia Gastrointestinal Therapeutics Market
- 8.6.5. South Korea Gastrointestinal Therapeutics Market
- 8.6.6. Rest of Asia Pacific Gastrointestinal Therapeutics Market
- 8.7. Latin America Gastrointestinal Therapeutics Market Snapshot
- 8.7.1. Brazil Gastrointestinal Therapeutics Market
- 8.7.2. Mexico Gastrointestinal Therapeutics Market
- 8.8. Middle East & Africa Gastrointestinal Therapeutics Market
- 8.8.1. Saudi Arabia Gastrointestinal Therapeutics Market
- 8.8.2. South Africa Gastrointestinal Therapeutics Market
- 8.8.3. Rest of Middle East & Africa Gastrointestinal Therapeutics Market
Chapter 9. Competitive Intelligence
- 9.1. Key Company SWOT Analysis
- 9.1.1. Company 1
- 9.1.2. Company 2
- 9.1.3. Company 3
- 9.2. Top Market Strategies
- 9.3. Company Profiles
- 9.3.1. Bristol-Myers Squibb Company
- 9.3.1.1. Key Information
- 9.3.1.2. Overview
- 9.3.1.3. Financial (Subject to Data Availability)
- 9.3.1.4. Product Summary
- 9.3.1.5. Recent Developments
- 9.3.2. AbbVie Inc.
- 9.3.3. Pfizer Inc.
- 9.3.4. AstraZeneca plc
- 9.3.5. Bayer AG
- 9.3.6. Takeda Pharmaceutical Company Limited
- 9.3.7. Organon Group of Companies
- 9.3.8. Bausch Health Companies Inc.
- 9.3.9. Cosmo Pharmaceuticals N.V.
- 9.3.10. Teva Pharmaceutical Industries Limited
Chapter 10. Research Process
- 10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
- 10.2. Research Attributes
- 10.3. Research Assumption
°ü·ÃÀÚ·á